The software provides analysis of HLA typing by NGS on several platforms, including ones from Illumina, Thermo Fisher, and PacBio.
The company said revenues from its non-invasive heart transplant rejection test AlloMap rose about 16 percent year over year.
Linkage is now part of Thermo Fisher's transplant diagnostics business, One Lambda. Linkage's flagship product line is its real-time PCR technology, LinkSeq.
The FDA approved the real-time PCR-based test for use on the Cobas 6800 and 8800 systems to assess the response of transplant patients to treatments.
The technology uses Thermo Fisher Scientific microarrays to measure transcript levels in order to diagnose rejection of solid organ transplants.
The company also said it has closed a new $25 million debt facility, and will use the proceeds to retire outstanding debt and bolster the launch of AlloSure.